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Steroids Do Not Prevent Photoreceptor Degeneration in the Light-
Exposed T4R Rhodopsin Mutant Dog Retina Irrespective of AP-1
Inhibition
Abstract
PURPOSE. AP-1 has been proposed as a key intermediate linking exposure to light and photoreceptor cell
death in rodent light-damage models. Inhibition of AP-1 associated with steroid administration also prevents
light damage. In this study the role of steroids in inhibiting AP-1 activation and/or in preventing
photoreceptor degeneration was examined in the rhodopsin mutant dog model.
METHODS. The dogs were dark adapted overnight, eyes dilated with mydriatics; the right eye was light
occluded and the fundus of the left eye photographed (∼15–17 overlapping frames) with a fundus camera. For
biochemical studies, the dogs remained in the dark for 1 to 3 hours after exposure. Twenty-four hours before
exposure to light, some dogs were treated with systemic dexamethasone or intravitreal/subconjunctival
triamcinolone. AP-1 DNA-binding activity was determined by electrophoresis mobility shift assay (EMSA)
and phosphorylation of c-Fos and activation of ERK1/2 were determined by immunoblot analyses. The eyes
were collected 1 hour and 2 weeks after exposure to light, for histopathology and immunocytochemistry.
RESULTS. Inhibition of AP-1 activation, and phosphorylation of ERK1/2 and c-Fos were found after
dexamethasone treatment in light-exposed T4R RHO mutant dog retinas. In contrast, increased AP-1 activity
and phosphorylation of c-Fos and ERK1/2 were found in triamcinolone-treated mutant retinas. Similar
extensive rod degeneration was found after exposure to light with or without treatment, and areas with
surviving photoreceptor nuclei consisted primarily of cones. Only with systemic dexamethasone did the RPE
cell layer remain.
CONCLUSIONS. Intraocular or systemic steroids fail to prevent light-induced photoreceptor degeneration
in the T4R RHO dog retina. Finding that systemic dexamethasone prevents AP-1 activation, yet does not
prevent retinal light damage, further supports the hypothesis that AP-1 is not the critical player in the cell-
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Exposed T4R Rhodopsin Mutant Dog Retina Irrespective of AP-1
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Abstract
PURPOSE—AP-1 has been proposed as a key intermediate linking exposure to light and
photoreceptor cell death in rodent light damage models. Inhibition of AP-1 associated with steroid
administration also prevents light damage. In this study the role of steroids in inhibiting AP-1
activation and/or in preventing photoreceptor degeneration was examined in the rhodopsin mutant
dog model.
METHODS—The dogs were dark adapted overnight, eyes dilated with mydriatics; the right eye was
light occluded and the fundus of the left eye photographed (∼15-17 overlapping frames) with a fundus
camera. For biochemical studies, the dogs remained in the dark for 1 to 3 hours after exposure.
Twenty-four hours before exposure to light, some dogs were treated with systemic dexamethasone
or intravitreal/subconjunctival triamcinolone. AP-1 DNA-binding activity was determined by
electrophoresis mobility shift assay (EMSA) and phosphorylation of c-Fos and activation of ERK1/2
were determined by immunoblot analyses. The eyes were collected 1 hour and 2 weeks after exposure
to light, for histopathology and immunocytochemistry.
RESULTS—Inhibition of AP-1 activation, and phosphorylation of ERK1/2 and c-Fos were found
after dexamethasone treatment in light-exposed T4R RHO mutant dog retinas. In contrast, increased
AP-1 activity and phosphorylation of c-Fos and ERK1/2 were found in triamcinolone-treated mutant
retinas. Similar extensive rod degeneration was found after exposure to light with or without
treatment, and areas with surviving photoreceptor nuclei consisted primarily of cones. Only with
systemic dexamethasone did the RPE cell layer remain.
CONCLUSIONS—Intraocular or systemic steroids fail to prevent light-induced photoreceptor
degeneration in the T4R RHO dog retina. Finding that systemic dexamethasone prevents AP-1
activation, yet does not prevent retinal light damage, further supports the hypothesis that AP-1 is not
the critical player in the cell-death signal that occurs in rods.
The differentiated photoreceptor is elegantly organized to have an external light-capturing
outer segment optimized for efficient quantal absorption. Internally, the inner segment has the
protein synthetic and energy-generating organelles, and on the vitreal aspect is the synaptic
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terminal that connects to the second-order neurons that ultimately transfer information to higher
visual centers. Each rod photoreceptor can be 120 μm or longer, and such exquisite
compartmentalization efficiently separates multiple specialized functions. Not surprisingly,
the photoreceptors' complexity, together with the specific signal transduction and
“housekeeping” functions performed, renders them susceptible to degenerative diseases, either
genetic or acquired, that result from damage to genes or pathways critical for their function or
viability. Of the 190 retinal disease loci mapped to date, the genes and mutations have been
identified for ∼135 (RetNet available at http://www.sph.uth.tmc.edu/RetNet/ provided in the
public domain by the University of Texas Health Science Center, Houston, TX). In many cases,
different mutations in the same gene result in a broad range of differing phenotypes, thus
emphasizing the broad genetic and allelic heterogeneity of these degenerative retinal disorders.
Of particular interest has been the interaction between light and the death of photoreceptors.
After Noell et al.1,2 made the seminal finding that visible light may damage mammalian
photoreceptors at intensities that are ordinarily encountered, many investigators in subsequent
studies have examined this interaction, especially in normal albino rodents, and have begun to
identify the pathways and molecular events that link exposure to light to photoreceptor
degeneration.3,4 Two different pathways, the bright- and low-light pathways, mediate light-
induced visual cell death, but only the bright-light pathway is accompanied by activation of
the AP-1 transcription factor.5 This critical intermediary has been proposed to link damaging
exposure to lights with photoreceptor apoptosis by activation of the c-Fos/AP-1 molecular
pathway.5
Photoreceptor degeneration also results from exposure to light in retinas having mutations in
the rhodopsin gene (RHO) that renders them especially sensitive to light. The naturally
occurring T4R6 and transgenic T17M7 RHO mutations in dogs and mice, respectively,
represent models for homologous diseases in humans with autosomal dominant retinitis
pigmentosa (adRP).8,9 Although these mutations affect the first- and second-consensus
glycosylation sequences,10 a possible indication of the enhanced light-damage susceptibility,
other RHO mutations in humans also show marked delays in visual pigment regeneration with
bleaching,11-13 a feature that raises concern as to the possible modulatory effect that exposure
to light can have on the disease process.6,14 Although light-induced damage in both normal
mice, and RHO mutant dogs or mice is mediated by RHO, the major difference between normal
and mutant subjects is that, in the latter, photoreceptors degenerate with light intensities that
cause no damage to normal retinas. Very short exposures to light, such as those used in routine
clinical eye examinations of humans, result in severe outer retinal degeneration.14,15
Previous studies in albino rodents using genetic or pharmacologic approaches have
demonstrated an association between AP-1 inhibition and prevention of photoreceptor
degeneration.16-18 Although there are some questions as to the specificity of this inhibition
and the role of AP-1 as a cell death or cell survival signal,19 it is clear that high-dose
administration of corticosteroids before exposure to light is associated with no photoreceptor
degeneration.18 In this study, we examined the effect of systemic or ocular corticosteroid
administration on AP-1 induction and photoreceptor degeneration. We found that only
systemic steroids inhibit AP-1 activation, but in neither case do steroids prevent or modulate
photoreceptor damage. This supports prior findings that, at least in the T4R RHO mutant canine
retina, AP-1 is not the critical player in the cell death signaling pathway that links exposure to
light and photoreceptor degeneration.19
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MATERIALS AND METHODS
Animals
Dogs were maintained at the Retinal Disease Studies (RDS) facility in Kennett Square (PA),
and all procedures were in adherence to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. The dogs represent an outbred population with a common
genetic background.20 The animal identification, genotype, ages studied, and procedures
performed are detailed in Table 1. At the ages studied and under the ambient light conditions
used in the kennels and procedure rooms (described later), the RHO mutants (T4R/+; T4R/
T4R) have no photoreceptor degeneration as long as ophthalmic examination procedures are
not performed.6,14
Treatment Protocols
Four different treatment protocols were performed to examine the effect of corticosteroids on
AP-1 activation and/or prevention of photoreceptor degeneration after clinical light exposures;
the steroids were administered either by systemic or direct ocular routes. All animals used and
procedures performed are listed in Table 1. As controls, we used 1 normal and 13 untreated
RHO mutants for biochemical (n = 8) and morphologic (n = 6) analyses; some of these dogs
were included in a previous study which characterized AP-1 and other signaling pathways that
were activated by exposure to light and are identified in the table.19
Study 1 consisted of six affected dogs used for biochemical (n = 3) and morphologic (n = 3)
analyses. The dogs were placed in constant darkness on the day before clinical exposure to
light, and received systemic dexamethasone (DEX) on the following schedule: Approximately
18 to 19 hours and again 4 to 5 hours before exposure to light, the dogs received subcutaneous
(SC) DEX (dexamethasone 2 mg/mL; Phoenix Pharmaceuticals, St. Joseph, MO) at an ∼dose
of 0.18 mg/kg. Two to 3 hours before exposure, a 10-fold higher dose of DEX (1.8 mg/kg) was
administered intravenously (IV).
Studies 2, 3 and 4 involved the ocular administration of corticosteroids before exposure to
light. Treatment was given to the light-exposed (n = 2), shielded (n = 3), or both the exposed
and shielded eyes (n = 4; Table 1). If a treatment effect was observed, this paradigm was
designed to determine whether it resulted from a direct or an indirect effect of the steroid in
the light-exposed eye. On the day before the clinical light exposure, the dogs were dark adapted.
Under dim red light illumination, the pupils were dilated with topical mydriatic solutions (1%
atropine, 10% phenylephrine, 1% tropicamide). The dogs were sedated with a combination of
intramuscular acetylpromazine/atropine and then anesthetized with IV ketamine. The treated
eyes had 150 μL of aqueous fluid removed by anterior chamber paracentesis and then were
injected with subconjunctival (Sconj) and intravitreal (IVit) triamcinolone acetonide (TRIAM;
Kenalog-40; Bristol-Meyers Squibb, Princeton, NJ). Each treated eye received ∼6 to 10 mg
Sconj and 6 mg IVit. At the ages studied, the vitreous volume of the treated dogs is ∼1.75 to
2.5 mL,21 and the IVit doses administered were in the range of 2.4 to 3.4 mg/mL of vitreous.
Exposure to Light and Tissue Collection
The animal housing and light-exposure conditions used in this study have been described in
detail previously,19 and are briefly summarized. Dogs were maintained in kennel runs in a
cyclic light environment (7 AM lights on/7 PM lights off) with light intensities that varied
between 175 and 350 lux at the level of the “standard” dog eye. For the clinical light exposures,
the dark-adapted dogs had the pupils dilated (1% tropicamide, 1% atropine, 10%
phenylephrine) in both eyes, and one eye was completely shielded from light (shielded). Under
dim red illumination, the other eye was exposed to a series of overlapping retinal photographs
(exposed) obtained with a hand-held, manual advance fundus camera (model RC-2; Kowa
Gu et al. Page 3
Invest Ophthalmol Vis Sci. Author manuscript; available in PMC 2010 July 1.
Company Ltd., Nagoya, Japan) within 4 to 5 hours of light onset (7 AM). With one exception,
the right eye was shielded, and the left eye was exposed (Table 1). Because the dog retina has
regions where the pigment epithelium is (inferior, nontapetal region) and is not (superior,
tapetal region) pigmented, different light intensities were used for viewing and photographing
these two regions. These adjustments were made with neutral density or gray polarizing film
filters and/or adjusting the settings of the photographic flash. For viewing, the approximate
retinal illuminances produced by the tungsten bulb were 0.95 and 3.8 mW · cm−2 respectively,
for the tapetal and nontapetal regions. For photography, microsecond duration flashes of a
xenon lamp produced approximate retinal doses/flash of 0.6 and 11 mJ · cm−2, respectively,
for the tapetal and nontapetal regions. Fifteen to 17 pictures were taken of the eye during an
∼5-minute period, and these were equally distributed between the tapetal and nontapetal zones.
Based on the light intensities used and activation of AP-1 by the exposure to light,19 we propose
that the light exposure paradigm used causes photoreceptor degeneration via the bright-light
pathway, although the genetic tools for testing independence from transducin signaling
presently are not available for such studies in the dog model.3,5 The use of multiple
microsecond-duration, bright-light flashes suggests damage by intermittent exposure to light,
which has been shown to be more damaging to the retina.1 However, the short interflash interval
used in our studies (∼17-20 seconds) differed from the 1-hour dark-adapted intervals used by
Noell et al.1 in their study of intermittent exposure to light1; thus a direct translation of those
studies is not possible.
After exposure to light, the dogs were returned to the dark and killed 1 to 3 hours later for
biochemical studies. For immunohistochemistry and conventional morphology, samples were
collected at 1 hour and 2 weeks, or at 2 weeks, respectively, after exposure. For the longer
postexposure time point, the dogs were returned to the regular kennel environment and
maintained under cyclic light conditions until they were killed 2 weeks after exposure.
For collections of retinas from exposed and shielded eyes, the dogs were anesthetized with
intravenous pentobarbital sodium in a dark room with dim red illumination, the eyes were
enucleated, and the dogs were euthanatized with a barbiturate overdose. The globes were
opened with a razor-blade cut anterior to the ora serrata, the posterior segment isolated, and
the vitreous removed. The retina was then manually separated from the pigment epithelium
and frozen at −80°C until use. For immunohistochemistry, the eyes were processed by using
standard techniques previously described.22
Preparation of Nuclear Protein Extracts
Nuclear protein extracts were prepared as described elsewhere.19,23 Briefly, single retina tissue
samples were homogenized in homogenization buffer (0.25 M sucrose, 15 mM Tris-HCl [pH
8.0], 60 mM KCl, 15 mM NaCl, 5 mM EDTA [pH 8.0], 1 mM EGTA [pH 8.0], 0.15 mM
spermine, 0.15 mM spermidine, 1 mM DTT, 0.5 mM PMSF, 5 μg/mL aprotinin, 2 μg/mL
leupeptin, and 2 μg/mL pepstatin), and after low-speed centrifugation, the supernatant was
saved as the postnuclear fraction. The pellet (crude nuclear fraction) was washed and extracted
with the extraction solution (20 mM HEPES [pH 7.3], 400 mM NaCl, 1 mM EDTA [pH 8.0],
1 mM EGTA [pH 8.0], 1 mM DTT, 0.5 mM PMSF, 5 μg/mL aprotinin, 2 μg/mL leupeptin,
and 2 μg/mL pepstatin), and the supernatant was collected by centrifugation and saved as the
nuclear protein extract. All postnuclear supernatant and nuclear extracts were stored at −80°C
until used; protein concentrations were determined with a DC protein assay kit (Bio-Rad
Laboratories, Hercules, CA) and normalized by silver staining of the gels that were analyzed
with a scanner and workstation (Storm 860 scanner; Amersham Biosciences, Pittsburgh, PA,
and ImageQuant workstation; Molecular Devices, Sunnyvale, CA) to determine protein
concentration.
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Probe Labeling
The probe for the electrophoresis mobility shift assay (EMSA) was a 21-bp double-stranded
AP-1 consensus oligonucleotide (5′-CGC TTG ATG AGT CAG CCG GAA-3′, 1.75 pM;
Promega, Madison, WI) labeled with γ-[32P]ATP (10 mCi/mL, 3000 Ci/mmol; Amersham
Biosciences) according to the phosphorylation reaction protocol in the gel shift assay system
manual (Promega). Unincorporated γ-[32P]ATP was removed by a spin column (Sephadex
G-25; Roche Diagnostics, Indianapolis, IN), and radioactivity was determined with a
scintillation counter (model LS6500; Beckman Coulter, Fullerton, CA).
Electrophoresis Mobility Shift Assay
EMSA was performed according to the manufacturer's instructions (Promega), as described
previously.19 All binding reactions between nuclear proteins (∼1.5 μg of protein/reaction) and
labeled probe (0.07 picomoles, ∼10,000 cpm/reaction), including the positive control HeLa
nuclear extract (>2.4 mg/mL; Promega), were examined by nondenaturing, gradient
polyacrylamide gels (2%-20%). Gels were dried and exposed to either of two phosphorescence
imagers (model BAS-IP 2040; Fujifilm Life Science, Stamford, CT, or PhosphorImager,
Amersham Biosciences) and/or x-ray films (Fujifilm Life Science). The images were scanned
and analyzed by a scanner with commercial software (BAS 1000, Image Gauge software;
Fujifilm Life Science), or the scanner and workstation described in the Probe Labeling section.
The relative AP-1 activity was determined based on the intensity of shifted bands measured
on a workstation normalized for equal protein loading by silver staining of the gels (Image
Gauge software, Fujifilm Life Science; or ImageQuant; Molecular Devices). Binding
specificity was confirmed by blocking reactions using unlabeled specific AP-1. The intensity
measurements obtained with the phosphorescence imager or x-ray films were comparable and
also with the radiation dose displayed in terms of units of photostimulated luminescence (PSL).
Immunoblot Assay
All immunoblot procedures were performed as previously described.19 One-dimensional
protein electrophoresis and immunoblot analysis was performed with nitrocellulose
membranes (Trans-Blot Transfer Medium, Bio-Rad Laboratories). The primary antibodies
used are listed in Table 2; HRP rabbit anti-mouse IgG and HRP goat anti-rabbit IgG (ZyMax,
San Francisco, CA) were used as the secondary antibodies. The immunoreacted bands were
detected by the enhanced chemiluminescence (ECL) system (Amersham Biosciences),
scanned, measured, and analyzed (ImageQuant; Molecular Devices).
Immunohistochemistry
A slit was made through the enucleated globe at the level of the ora serrata, and the entire globe
was fixed for 1 hour in 4% paraformaldehyde in 0.1 M phosphate-buffered saline at 4°C. The
posterior segment then was isolated, the vitreous gently removed, and the eye cup fixed for an
additional 2 hours at 4°C in 2% paraformaldehyde in 0.1 M phosphate-buffered saline. The
eye cup was then transferred to 2% paraformaldehyde in 0.1 M phosphate-buffered saline for
24 hours. The tissue was trimmed, cryoprotected sequentially for 24 hours in a solution of 15%
and 30% sucrose in 0.1 M sodium phosphate and 0.15 M sodium chloride, pH 7.2 (BupH
phosphate-buffered saline; Pierce, Rockford, IL), at 4°C, and embedded in optimal cutting
temperature (OCT) medium. Retinal cryosections along the superior and inferior retinal
meridians of both the light-exposed and shielded eyes from RHO mutant dogs were cut at 7-
μm thickness and used to examine the cellular localization of the AP-1 complex component
phosphorylated c-Fos, and phosphorylated ERK1/2 (Table 2) using standard
immunofluorescence protocols.24 Double-immunofluorescence with CRALBP was performed
to determine colocalization in Müller cells. Labeling with GFAP and RPE65 determined the
reactivity of Müller cells, and the integrity of the RPE in exposed mutant retinas. Double-
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labeling with human cone arrestin and rod opsin identified the remaining photoreceptor cells
in the areas of retinal atrophy.
Conventional Retinal Morphology
Immediately after enucleation, the posterior segments were isolated and fixed in a triple-
fixative protocol (3% glutaraldehyde-2% formalde-hyde 2% glutaraldehyde-1% osmium
tetroxide, and 2% osmium tetroxide), as previously reported.25 The posterior segments were
trimmed into segments that extended from the optic nerve to the ora serrata along the superior
and inferior meridians, dehydrated, and embedded in epoxy resin (PolyBed 812; Polysciences,
Warrington, PA). Full-length 1-μm sections were cut with glass knives, stained with azure II-
methylene blue, with or without a paraphenylenediamine counter stain. The sections were
examined in contiguous fields from the optic disc to the ora serrata, and representative images
from the same retinal location photographed (Spot 4.0 camera; Diagnostic Instruments, Inc.,
Sterling Heights, MI).
RESULTS
Effect of Systemic DEX on AP-1 DNA Binding Activity in Exposed RHOMutant Retina
We have described that clinical light exposure of the T4R RHO mutant retina results in an
∼2.5- to 3.5-fold increase in AP-1 DNA-binding activity. Increased binding occurred within
1 hour of exposure, remained elevated for 6 hours, and decreased to normal (pre-exposure or
shielded levels) by 24 hours. Activation of AP-1 by light was specific to the RHO mutant retina
and did not occur either in normal controls or animals with prcd, a nonallelic retinal disease.
19,20 After systemic DEX, there was a marked inhibition of AP-1 activation after exposure to
light of the RHO mutant retina (Figs. 1A, 2A). In comparison to untreated animals that showed
increases in retinal AP-1 binding of ∼2.6-fold (Figs. 1A-C), the levels increased 1.2- to 1.3-
fold with DEX treatment (Fig. 2A).
Effect of Ocular TRIAM on AP-1 DNA Binding Activity in Exposed RHO Mutant Retina
In contrast, we found minimal inhibition of AP-1 activation in mutant retinas that were treated
by direct ocular injection of TRIAM. Exposure to light after treatment of the exposed eye
showed distinct AP-1 activation (Fig. 1B), with increases ranging from 1.5- to 2.6-fold (Fig.
2B). Similar increases were observed whether the TRIAM was administered to the shielded
eye or to both exposed and shielded eyes (Figs. 1C, 2C). Treatment with ocular TRIAM of a
normal control dog in both eyes showed the expected lack of AP-1 activation by clinical light
exposure (Fig. 2C).
Effect of Ocular TRIAM or Systemic DEX on Phosphorylation of c-Fos
A distinct 50-kDa c-Fos band was found by immunoblot analysis in the untreated, shielded
mutant retina that was the same as in the light-exposed or shielded normal retina (N164). A
second immunoreactive band of ∼56 kDa, indicative of phosphorylated c-Fos,19 was observed
in the exposed mutant retina (Fig. 3, EM60, compare lanes from shielded and exposed retinas).
The same is observed in the exposed TRIAM treated, but not the shielded retina (Fig. 3,
EMB18). In contrast, exposed retinas of DEX-treated dogs showed a smear at the p-c-Fos
position (Fig. 3; EM59, EM67). This result suggests that systemic DEX partially inhibits c-
Fos phosphorylation at some residues. In all cases, a lower molecular mass band, ∼ 45 kDa,
of variable intensity was present in all samples and was assumed to represent nonspecific
binding of the antibody or a lower molecular mass isoform of c-Fos.
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Steroids, Exposure to Light, and ERK1/2 Phosphorylation
We previously demonstrated that extracellular regulated kinase (ERK), an upstream activator
of AP-1,26 is phosphorylated in the RHO mutant retina after exposure to light, and the activation
time course is similar to that of AP-1.19 In the present study, we examined the effect of systemic
or ocular steroids on ERK1/2 phosphorylation after exposure to light. In the untreated, exposed
mutant retina, ERK1/2 phosphorylation occurred by 1 hour after exposure to light, and levels
were ∼4 (p-ERK1)- and ∼2.5 (p-ERK2)-fold higher than in the contralateral shielded retina
(Figs. 4A, 5A). Systemic DEX markedly inhibited ERK1 (1.4- to 1.6-fold) and -2 (1.2- to 1.4-
fold) phosphorylation (Figs. 4A, 5A). Direct application of ocular TRIAM to the exposed eye
resulted in a variable ERK1/2 phosphorylation response (Figs. 4B, 5B). One retina showed
minimal ERK phosphorylation (EM65), but the rest showed ERK1 phosphorylation levels that
ranged from 2.5- to 3.6-fold higher than the untreated shielded eye (Fig. 5B). Similar results
were observed in the exposed retinas when the direct ocular TRIAM treatment was applied to
the shielded eye (Figs. 4C, 5C). With direct ocular steroid treatment, either to the exposed or
to the shielded eye, the effect on ERK phosphorylation, although variable, appeared to be more
pronounced on ERK2 than on ERK1.
Effect of Ocular or Systemic Steroids on Retinal Degeneration after Exposure to Light
Two weeks after clinical light exposure, the untreated, exposed RHO mutant retina showed
advanced outer retinal degeneration, and the findings were similar for both the central tapetal
(Rerior) and nontapetal (inferior) regions—areas where the RPE, respectively, is not or is
pigmented. There was a nearly complete loss of all photoreceptors and their nuclei. As the RPE
layer had degenerated and disappeared as an anatomically distinct cell layer, the external
limiting membrane now rested on a markedly attenuated choriocapillaris. Although these
abnormalities were quite uniform in the exposed regions, it is important to note than some
localized regions retained one to two incomplete rows of outer nuclear layer (ONL) nuclei and
degenerating photoreceptor inner segments. In addition, the nontapetal layer showed
hypertrophied and detached RPE cells that had migrated intraretinally (Figs. 6A1, 6A2). The
shielded retina, on the other hand, was morphologically normal (Figs. 6A3, 6A4).
Treatment with systemic DEX before light exposure did not prevent outer retinal degeneration
in the exposed eyes. The pathologic abnormalities were similar to that observed in untreated
mutant retinas, although more areas in the treated eye retained one to two incomplete rows of
ONL nuclei and degenerating photoreceptor inner segments (Figs. 6B1, 6B2). Moreover, in
both the DEX-treated and untreated mutant retinas, cone nuclei comprised most of the surviving
photoreceptor nuclei in the ONL (Figs. 7A3-C3). Systemic DEX did not cause any adverse
retinal effects, and the shielded mutant retina remained normal (Figs. 6B3,6B4). However, the
exposed retina of the DEX-treated animals had two salient differences from untreated, exposed
retinas (Figs. 6B1, 6B2, 7). First, there was preservation of an RPE monolayer that, although
structurally compromised and slightly attenuated, still expressed low levels of RPE65 protein
(compare Figs. 7A1, 7A2 with 7C1, 7C2). Second, there was Rpression of activation of Müller
cells, and glial processes did not extend into the subretinal space. (Figs. 7A2-C2).
Direct ocular administration of TRIAM also did not modify the light-induced retinal
degeneration that was observed in mutant retinas 2 weeks after exposure to light. In contrast
to systemic DEX, there was no preservation of RPE cells (Figs. 6C1, 6C2). In some areas, cells
with the cytologic characteristics of macrophages were located adjacent to Bruch's membrane
or intraretinally, and contained multiple cytoplasmic inclusions characteristic of undegraded
susbtrate in lysosomes (Fig. 6C1; data not shown). Significantly, direct ocular administration
of TRIAM did not have an adverse effect in the shielded mutant retina (Figs. 6C3, 6C4), or the
normal retina, whether shielded or exposed (Figs. 6D1-D4).
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Light-Induced c-Fos and ERK1/2 Phosphorylation in Müller Cells Despite Steroid Treatment
One hour after exposure to light, c-Fos and ERK1/2 phosphorylation was observed in the
somata of Müller cells (Figs. 8A1, 8A2; 9A1, 9A2), as previously reported19. Steroid treatment
(systemic DEX, or ocular TRIAM) did not prevent phosphorylation of c-Fos (Figs. 8B1,
8C1) in Müller cells after exposure to light. Since the antibody we used is directed against c-
Fos phosphorylated on Ser374, our results suggest that steroids do not prevent phosphorylation
at this residue.
Phosphorylation of ERK1/2, on the other hand, was significantly reduced after steroid
treatment and was predominantly restricted to the somata of Müller cells. No such
colocalization of p-c-Fos and p-ERK1/2 with CRALBP was seen in shielded eyes (Figs. 8B2,
8C2; 9B2, 9C2). These findings support the immunoblot results and show that both steroids
treatment (DEX and TRIAM) decrease the levels of pERK1/2 staining in Müller cells of the
light-exposed eyes (Figs. 9B1, 9C1) in comparison to what is observed in the untreated retinas
(Fig. 9A1). Although those levels are decreased, weak labeling persists, suggesting that steroids
do not fully inhibit the light-induced ERK1/2 phosphorylation (compare Figs. 9B1, 9B2 with
9C1 9C2).
DISCUSSION
A critical intermediary identified in experimental retinal light damage is activation of the AP-1
transcription factor. It has been proposed that light induces photoreceptor apoptosis in wild-
type mice by activation of the c-Fos/AP-1 molecular pathway.5 As a transcription factor, AP-1
has varied functions in many biological processes, among which are cell transformation,
proliferation, differentiation, apoptosis, and survival.27-29 Such functions, which often appear
to have opposite effects, most likely depend on the tissue, the stimulus, and the signaling
pathway(s) involved.
In the T4R RHO mutant dog retina, we have found three early biochemical events associated
with clinical exposure to lights that subsequently are associated with photoreceptor
degeneration. Activation of ERK1/2, c-Fos phosphorylation and induction of AP-1 DNA
binding activity occur within 1 hour of exposure to light, and all have a similar magnitude and
time course.19 Phosphorylation of ERK1/2 in the mutant retina appears limited to the dog, as
normal albino mice do not show retinal ERK1/2 activation with damaging exposure to lights.
30 The downstream targets of this putative signaling pathway have not been identified yet,
although our studies show that the biochemical events occur in Müller cells and not
photoreceptors, a possible indication that the signaling pathway is a cell survival rather than
cell death response.19
Inhibition of AP-1 by genetic manipulation (c-Fos knockout16) or activation of the
glucocorticoid receptor by food deprivation or exogenous DEX18 is associated with prevention
of light-induced retinal degeneration in wild-type mice. This is a compelling therapeutic target
for translational studies in this mutant dog model, particularly because steroids are approved
for human use by various routes of administration, and the potential for light damage is of
concern for some human retinal degenerative disorders besides those caused by RHO
mutations.14,31 We reasoned that if the protective effect of steroids on retinal light damage
could be replicated in the canine model, then alternate delivery systems that lessen systemic
and/or intraocular exposure and side effects, e.g., iontophoresis, could be tested experimentally
before therapeutic use in humans. To date, only infrared imaging can be used for clinical
examinations14 or surgical intervention32 in the highly light-sensitive RHO mutant canine
retina.
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To this end, we performed a series of studies examining the effect of systemic DEX or direct
ocular administration of TRIAM on both the known components of the AP-1 signaling pathway
in the mutant canine retina, and on the prevention of photoreceptor degeneration. The dose of
DEX was more than 10-fold higher than that used in dogs in emergency situations to provide
an acute anti-inflammatory effect (0.05- 0.1 mg/kg IV; Wadell L, School of Veterinary
Medicine, University of Pennsylvania, Philadelphia, PA, written communication, June 2008).
Similarly, the doses of TRIAM are comparable to or higher than those used clinically to
suppress severe extraocular or intraocular inflammation. In humans, 2- to 4-mg doses of IVit
TRIAM are used in the treatment of refractory, clinically significant diabetic macular edema,
33 and 4 mg for most other intraocular diseases,34 although higher doses may be used.35 In
dogs, IVit injections of 8 mg TRIAM in a 0.2-mL volume without anterior chamber
paracentesis caused immediate, but transient elevations of intraocular pressure (IOP);
thereafter, the IOP returned to baseline and remained normal.36 Thus, the single IVit TRIAM
injection at the doses used in this study achieve immediate therapeutic levels that, based on
clinical experience with dogs with intraocular inflammation, lasts 5 to 6 weeks and has no
adverse effect.
We found that IV DEX, in contrast to IVit TRIAM, caused a profound inhibition of AP-1
activation. Although AP-1 DNA-binding activity with DEX was much lower than that in
untreated light-exposed retinas, the DNA binding activity in TRIAM-treated eyes in most dogs
was minimally inhibited. Because of the potential that an effect from IVit TRIAM could arise
indirectly from systemic circulation rather than locally, we performed injections in the exposed
eye, the shielded eye, or both eyes. In all cases, the results were comparable. Lack of systemic
effect from TRIAM absorption is not unexpected given that in most patients there are no
detectable levels of TRIAM in serum after IVit administration of 20 to 25 mg.37
In parallel with increased AP-1 DNA binding activity, there was a distinct c-Fos
phosphorylation pattern in untreated mutant retinas exposed to light,19 and in exposed eyes
treated with IVit TRIAM. The latter result was interpreted as no effect on c-Fos
phosphorylation by locally administered steroids. In contrast, the exposed mutant retinas of
dogs receiving IV DEX showed light labeling and a smear at the p-c-Fos position suggesting
partial c-Fos phosphorylation. As there are multiple serine/threonine phosphorylation sites in
the c-Fos protein structure,38,39 complete phosphorylation of c-Fos should form a clear
phosphorylated c-Fos band in immunoblot images. However, if the phosphorylation process
is interrupted, just some of these sites are phosphorylated. Such partially phosphorylated c-Fos
proteins would form a smear in electrophoresis as seen in the mutant retinas from animals
treated with IV DEX.
Similarly, administration of steroids by the systemic or ocular routes produced different
outcomes in terms of ERK1 and -2 phosphorylation. In the untreated mutant retinas, ERK1/2
phosphorylation occurred by 1 hour after exposure to light, and the levels were approximately
three- to fourfold higher than in the shielded retinas.19 Systemic DEX caused a marked
inhibition of ERK1/2 phosphorylation, and this was much more pronounced than the more
modest and slightly variable inhibition caused by locally administered TRIAM. With TRIAM,
the results were the same whether the exposed or the shielded eyes were treated. If one assumes
that dogs, like humans, show limited to no absorption of intravitreally administered TRIAM,
37 then the results indicate lack of effect of locally administered TRIAM on ERK1/2
phosphorylation.
In summary, our biochemical results demonstrate that systemic DEX inhibited the principal
components of the AP-1 molecular pathway after exposure to light of the T4R RHO mutant
retina. In contrast, locally administered TRIAM had no to minimal effects on ERK1/2
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activation and c-Fos phosphorylation; similarly, the effects on AP-1 DNA binding activity are
equally modest.
Regardless of whether systemic or ocular steroids modify the AP-1 signaling pathway, an
important question is whether they prevent or modify the retinal degeneration that results from
clinical exposure to lights. Although there were some treatment-related differences in the
response of the retina to light, it was clear that end-stage retinal degeneration was the common
outcome of clinical light exposure regardless of treatment, and, in the degenerate retina, the
predominant photo-receptor class that survived were cones. Preservation of RPE cells in retinas
from animals treated with IV DEX was a prominent finding, even though the outer retinal
degeneration was similar whether the RPE cell layer was present or absent. RPE damage and
degeneration associated with exposure to light is a feature of the RHO mutant dog retina, and
also occurs in normal albino rats with light-induced damage, although the timing of
photoreceptor and RPE apoptosis is different between the two cell types.1,40 RPE degeneration
secondary to light-induced damage is not a significant finding in wild-type mice4 or T17M
RHO mutant mice (Lewin A, personal communication, June 2008), suggesting that the RPE
response to similar light insults is species specific.
Systemic DEX also resulted in marked suppression of the GFAP activation of Müller cells.
The untreated, exposed mutant retina showed GFAP expression extending throughout the
radial fibers. The Müller processes projected into the subretinal space and coursed parallel to
the external limiting membrane. Although this is a feature reported for many chronic
photoreceptor degenerations,41 previously we have not observed such a Müller cell response
in dogs.24 This effect may be related to the acute disruption of the external limiting membrane
caused by exposure to light. A similar outgrowth of Müller cells into the subretinal space has
been reported in animal models of retinal detachment as well as in human tissue samples.42
To localize the components of the AP-1 signaling pathway in the treated retinas and
complement the biochemical analyses, we used immunohistochemistry to examine p-c-Fos
and p-ERK1/2 expression. As in light-exposed untreated mutant retinas,19 these proteins were
localized in Müller cells as evident by their colocalization with CRALBP. In both TRIAM-
and DEX-treated animals, both p-c-Fos and p-ERK1/2 were expressed in Müller cells of light-
exposed eyes. For p-c-Fos, there were no qualitative differences noted between light-exposed
DEX- and TRIAM-treated mutant retinas. In contrast, immunohistochemistry confirmed the
immunoblot analysis results by showing a decrease in ERK1/2 phosphorylation after steroid
treatment.
Our results are not in agreement with those in published studies implicating the AP-1 molecular
pathway in light-induced photoreceptor degeneration (see Refs. 4, 19 for review). This
molecular pathway has been proposed, in part, by finding that photoreceptor degeneration is
prevented through the inhibition of AP-1 by activation of the glucocorticoid receptor in wild-
type mice.18 Although IV DEX markedly suppressed the known components of the AP-1
signaling pathway in the canine retina, photoreceptor degeneration was not prevented, even
though systemic DEX appeared to protect the RPE and inhibit Müller cell reactivity. One could
argue that the doses used are “subtherapeutic” as a dose-response curve was not calculated,
and higher doses may have prevented the degeneration. Although that is true, we posit that the
doses used either locally or systemically were quite high, particularly with IV DEX, of which
we used doses 10- to 20-fold higher than that used in emergency situations. In contrast, AP-1
inhibition through activation of the glucocorticoid receptor in mice required a dose of 52 mg/
kg of dexamethasone, and lower doses (e.g., 22 and 37 mg/kg), only offered partial protection.
18 Such suprapharmacologic doses in mice may well have broader effects than those associated
with AP-1 inhibition and are problematic to extrapolate to larger species such as dogs or
humans.
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Our studies further support the hypothesis that the signaling components of the AP-1 molecular
pathway are localized to Müller cells, not to the photoreceptors, and support a role for AP-1
in cell survival, rather than cell death.19 The localization of this pathway to Müller cells is not
influenced by pretreatment with steroids (Fig. 10). Müller cell reactivity after a diverse array
of retinal injuries is thought to promote an initial survival response through the release of
neurotrophic factors and antioxidants43-45 after the early, nonspecific ERK activation and
upregulation of GFAP expression.46 If these responses are survival rather than cell death
signals, why then does the steroid-treated retina not show greater damage, especially with IV
DEX, than the untreated mutant retinas? This may depend on the light intensity used, so that
overwhelming damage occurs and modulation of degeneration, either worsening or
ameliorated, cannot be recognized. Establishing threshold intensities for these lesions will
allow these hypotheses to be tested experimentally.
Last, although AP-1 has been ruled out as the critical player in the cell-death signal and studies
are now in progress to identify other candidate molecules that play a role in cell death or
survival, it is of equal importance to consider how the mutant opsin triggers disease, as this is
informative regarding disease mechanisms that can be tested experimentally. Gaining this
information will require examination of the interaction of ambient light versus exposure to
bright light, the effect of serial graded bleachings that are not damaging after single exposure,
and the effect of full rhodopsin bleaching in light-adapted versus dark-adapted retinas. These
studies are now in progress.
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FIGURE 1.
EMSA of AP-1 DNA-binding activity in retinal nuclear proteins from T4R RHO mutant dogs
1 hour after light exposure. The dogs were untreated or treated with systemic DEX (A) or were
treated locally with TRIAM in the exposed (E) eye (B), the shielded (S) eye, or both (B) eyes
(C). The exposed retina of the untreated dog (EM60) showed a marked increase in AP-1
binding, but it was suppressed by DEX treatment (EM67). Retinas receiving TRIAM in the E,
S, or B eyes showed increased AP-1 binding in the exposed eye. The description below the
gels represent the genotype at the RHO locus, the postexposure (PE) interval, and the treatment.
The dashed lines in the gels indicate that the images represent lanes from the same gel that
were not adjoining.
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FIGURE 2.
The AP-1 binding activity ratio (E/S, exposed/shielded) in retinas after exposure to light. (A)
Without treatment, AP-1 levels increased significantly 1 hour after light exposure, but DEX
pretreatment inhibited AP-1 activation. (B) Pretreatment with TRIAM in the exposed (E), or
(C) shielded (S) or both (B) eyes resulted in minimal to no AP-1 inhibition. (C) The exposed,
normal retina (EM102) did not show any increase in AP-1-binding activity. Note that the AP-1
binding ratio for untreated affected dogs in (C) (EMB29, -30, -34) represents the average of
the three ratios. The description below the histograms represent the genotype at the RHO locus,
the postexposure (PE) interval, and the treatment.
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FIGURE 3.
c-Fos immunoreactive pattern in nuclear proteins of light-exposed (E) or shielded (S) retinas.
The normal retina (N164) showed a distinct c-Fos band of ∼50 kDa, and there were no
differences between E and S eyes. The untreated, affected mutant retina (EM60) also showed
a pattern similar to normal in S eye, but exposure to light (E) resulted in the appearance of a
higher molecular mass band at ∼56 kDa, which represents phosphorylated c-Fos.19 Direct
ocular treatment with TRIAM did not prevent c-Fos phosphorylation (EMB18). Exposure to
light after systemic DEX resulted in a smear in the p-c-Fos position, an indication of slight and
partial c-Fos phosphorylation (EM59, EM67). The description below the gels represents the
genotype at the RHO locus, the postexposure (PE) interval, and the treatment. The dashed
lines in the gels indicate that the images represent lanes from the same gel that were not
adjoining.
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FIGURE 4.
Phosphorylated ERK1/2 in retinal postnuclear Rernatant fractions from T4R RHO mutant dogs
1 hour after exposure to light. (A) Comparable levels of phosphorylated ERK1/2 were detected
by immuno-blot analysis in both light-exposed (E) and shielded (S) retinas of a dog treated
with systemic DEX (EM67), but a significantly increased level of p-ERK1/2 was found in the
exposed retina of untreated mutant (EM66). (B, C) Increased p-ERK1/2 levels in the E retinas
were found in animals in which the TRIAM was administered to the exposed (B) or shielded
(C) eyes. There was some degree of variability in the level of p-ERK1/2 phosphorylation in
the exposed retinas of TRIAM-treated eyes, but all showed increased p-ERK1/2 levels with
exposure to light. Tubulin or β-actin immunoblots were used as a loading control for
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normalization. The lines below the p-ERK1/2 gels represent the genotype at the RHO locus,
and the treatment. The dashed lines in the gels indicate that the images represent lanes from
the same gel that were not adjoining.
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FIGURE 5.
Ratios of phosphorylated ERK1/2 (E/S, exposed/shielded) in T4R RHO mutant retinas 1 hour
after light exposure. (A) Untreated, exposed mutant retinas showed a marked increase in p-
ERK1/2, but it was inhibited by systemic DEX. The exposed retinas showed light-dependent
increases in p-ERK1 and p-ERK2 after treatment with TRIAM, which was administered to the
exposed (B) or shielded (C) eyes. In general, p-ERK1/2 levels were variable between animals,
and increases were more marked in p-ERK1 than for p-ERK2. The lines below the histograms
represent the genotype at the RHO locus, and the treatment.
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FIGURE 6.
Photomicrographs of plastic-embedded retinal sections from eyes collected 2 weeks after
clinical exposure to light. Images were taken approximately 1250 μm from the optic disc along
both the superior (A1, A3; B1, B3; C1, C3; D1, D3) and inferior (A2, A4; B2, B4; C2, C4; D2,
D4) meridians from the exposed (A1, A2; B1, B2; C1, C2; D1, D2) and shielded (A3, A4; B3,
B4; C3, C4; D3, D4) eyes. (A) The untreated mutant (EM109) showed extensive outer retinal
degeneration and loss of RPE in the exposed retina, but the shielded retina was normal; (A2,
arrow) intraretinal pigmented cell. (B) Systemic DEX (EM110) the photoreceptors and outer
retinal layers degenerated in the exposed eye, but the shielded retina was normal. An
incomplete, and structurally compromised RPE layer remained (B1, B2, *), and the ONL
consisted of one to two incomplete rows of nuclei. (C) Sconj and IVit TRIAM administered
to both eyes (OU) of a mutant dog (EM103) before exposure to light did not prevent RPE,
photoreceptor, and outer retinal degeneration. Note presence of hypertrophied cells external
to the inner nuclear layer (INL) with cytoplasmic inclusions that have cytologic characteristics
of macrophages (C1, arrows). The TRIAM-treated shielded, mutant retina remained normal
(C3, C4). (D) Intravitreal TRIAM administered to both eyes (OU) of a normal dog (EM100)
before exposure to light caused no adverse effects in the exposed or shielded retinas. OS, outer
segment layer; IS, inner segment layer; OPL, outer plexiform layer. Scale bar, 20 μm.
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FIGURE 7.
Morphologic and immunohistochemical characterization of the retina from light-exposed
(EM108, OS; EM112, OS) and shielded (EM112, OD) T4R RHO mutant dogs; dog EM108
was treated with systemic DEX, and dog EM112 was not treated. All sections from an
individual eye were from a series of serial sections taken from the same region. (A1) Marked
thinning of the ONL, and loss of photoreceptor inner and outer segments in the DEX-treated,
light-exposed mutant retina. Note the preservation of the RPE (arrows). (B1) Similar loss of
photoreceptors in the untreated, light-exposed retina. Note, however, the absence of the RPE.
(C1) Normal retinal structure and lamination in the shielded eye. (A2) Weak RPE65 labeling
(arrows; green) and absence of GFAP labeling (red) in the DEX-treated light-exposed mutant
retina. (B2) Strong GFAP labeling in the untreated, light-exposed retina; the absence of RPE65
labeling resulted from RPE loss. (C2) The shielded mutant retina was normal, and RPE labeling
was intense and distinct. (A3) The majority of the remaining cell somata in the ONL of the
DEX-treated, light-exposed mutant retina were human cone arrestin (hCAR) positive
(arrowheads; red); punctate labeling of some cells with the rod opsin antibody is also present
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(arrows; green). (B3) Similar findings in the untreated, light-exposed retina. (C3) Normal
pattern of rod opsin (green) and hCAR (red) labeling in the shielded mutant retina. TL, tapetum
lucidum; OS, outer segments; IS, inner segments; INL, inner nuclear layer; GCL, ganglion cell
layer. Scale bar, 20 μm.
Gu et al. Page 22
Invest Ophthalmol Vis Sci. Author manuscript; available in PMC 2010 July 1.
FIGURE 8.
Double fluorescence immunohistochemistry with p-c-Fos (green) and CRALBP (red)
antibodies in T4R RHO mutant retinas 1 hour after exposure to light. Images were taken from
the midperipheral region of the superior retinal meridian in light-exposed (A1, B1, C1) and
shielded (A2, B2, C2) eyes of untreated animals (No Rx), or after steroid administration
(systemic DEX or ocular TRIAM). Colocalization of p-cFos and CRALBP was seen in the
Müller cell somata of the light-exposed retinas (A1: EM141 OS; B1: EM227 OS; and C1:
EM226 OS) but not in the shielded eyes (A2: EM142 OD; B2: EM227 OD; and C2: EM226
OD). Scale bar: 20 μm.
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FIGURE 9.
Double fluorescence immunohistochemistry with p-ERK1/2 (green) and CRALBP (red)
antibodies in T4R RHO mutant retinas 1 hour after exposure to light. Images were taken from
the midperipheral region of the superior retinal meridian in light-exposed (A1, B1, C1) and
shielded eyes (A2, B2, C2) of untreated animals (No Rx) or after steroid administration
(systemic DEX or ocular TRIAM). Colocalization of p-ERK1/2 and CRALBP was seen in the
Müller cell somata of the light-exposed retinas (A1: EM141 OS; B1: EM227 OS; and C1:
EM226 OS) but not in the shielded eyes (A2: EM142 OD; B2: EM227 OD; and C2: EM226
OD). p-ERK1/2 labeling was reduced in the exposed retinas treated with either systemic DEX
(B1: EM227 OS), or ocular TRIAM (C1: EM226 OS) in comparison with that observed in the
untreated exposed retina (A1: EM141 OS). Scale bar, 20 μm.
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FIGURE 10.
The events that occur after clinical light exposure that cause photoreceptor degeneration in the
T4R RHO mutant retina in the presence or absence of systemic DEX. In the untreated mutant
retina, exposure to light resulted in phosphorylation of ERK1/2 and c-Fos and increased DNA
binding by AP-1 (AP-1 activation). Our previous results suggest that AP-1 activation results
in a cell survival response initiated in Müller cells.19 Treatment with systemic DEX inhibits
phosphorylation of ERK1/2 and c-Fos, and AP-1 DNA binding activity is not increased. This
may result in a decreased cell survival response mediated by Müller cells. However, regardless
of systemic DEX treatment, clinical light exposure of the T4R RHO mutant retina leads to
photoreceptor cell death.
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Table 2
Antibodies
Antigen Host Source* IB IHC
c-Fos (4) Rabbit pc Santa Cruz Biotech, Santa Cruz, CA; sc-52 (0.2
μg/μL)
1:500
P-c-Fos (Ser374) Mouse mc Assay Designs; 905–640 1:10
P-ERK (E-4) Mouse mc Santa Cruz Biotech; sc-7383 (0.2 μg/μL) 1:1,000
P-ERK1/2 Mouse mc Cell Signaling, Beverly, MA; 9106 1:30
β/3-Actin Mouse mc Chemicon, Temecula, CA; MAB1501 1:1,000
Tubulin Mouse mc Santa Cruz Biotech; sc-23950 (0.2 μg/μL) 1:5,000
CRALBP Rabbit pc Jack Saari (University of Washington, Seattle,
WA)
1:1,500
GFAP Rabbit pc DakoCytomation, Carpinteria, CA; Z0334 1:1,000
RPE65 Mouse mc Novus Biologicals; NB-100-355 1:500
Rod opsin Mouse mc Chemicon; MAB5316 1:1,000
Human cone arrestin Rabbit pc Cheryl Craft, LUMIF (University of Southern
California, Los Angeles, CA)
1:10,000
AF488 2ary anti-mouse Goat Invitrogen, Carlsbad, CA; A-11029 1:200
AF568 2ary anti-rabbit Goat Invitrogen; A-11036 1:200
P, phosphorylated; pc, polyclonal; mc, monoclonal; IB, immunoblot analysis; IHC, immunohistochemistry; 2ary, secondary.
*
Catalog numbers for commercially available antibodies are listed as a reference to their specificity.
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